Collectively, these in vitro and in vivo findings establish SMC4 as a critical facilitator of glioma metastasis by potently activating the TGF-β/SMAD signaling axis, highlighting its therapeutic potential as a target for inhibiting metastatic progression in glioma. The gene discussed is TGFB1; the disease is central nervous system cancer.